medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2012, Number 05

<< Back Next >>

Ginecol Obstet Mex 2012; 80 (05)

Booster Vaccination Against Bordella Pertussis During Pregnancy

Esteves-Jaramillo A, Gómez ACM, Esparza AM, López-Collada VLR

Language: Spanish
References: 30
Page: 341-347
PDF size: 233.59 Kb.


ABSTRACT

During the last decades, the incidence of whopping cough, has been rising worldwide, despite the high coverage of the immunization programs. The highest mortality is found among children under 6 month of age, who are too young to have completed a primary vaccination series with three doses the pertussis vaccine, nevertheless this disease also affects adolescents and adults, who may only manifest mild symptomatology. Hence they do not get diagnosed or treated, becoming a potential community source of infection for young children. In order to prevent this transmission, the recommendation of vaccinating adolescents and adults, including of women in child bearing age, was issued. Nevertheless the immunization coverage among these populations was low. Postpartum vaccination was also recommended, but recent evidence have shown that the antibody levels in breast milk are detectable at least a week after immunization, allowing a window of opportunity for the infection in the newborn.
Finally, it has been suggested that a booster dose against Bordetella pertussis, given to pregnant women is safe and immunogenic. Therefore, the antibody transferred across the placenta and through breast milk, could protect the product in the early stages of life.


REFERENCES

  1. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326-382.

  2. Atkinson W, Wolfe C, Hamborsky J, McIntyre L, eds. Epidemiology and prevention of vaccine-preventable diseases, 11th ed. Washington: Public Health Foundation, 2009.

  3. Muñoz FM. Pertussis in infants, children, and adolescents: diagnosis, treatment and prevention. Semin Pediatr Infect Dis 2006;17:14-19

  4. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B. Sentinel Health Unit Surveillance System Pertussis Working Group. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001;32:1691-1697.

  5. Christie CD, Baltimore RJ. Pertussis in neonates. Am J Dis Child 1989;143(10):1199-1202.

  6. Granström G, Sterner G, Nord CE, Granström M. Use of erythromycin to prevent pertussis in newborns of mothers with pertussis. J Infect Dis 1987;155:1210-1214.

  7. Immunization, vaccines and biologicals [internet]. Ginebra (Suiza). World Health Organization, 2011 -[citado 2011, Noviembre 30]. Disponible en: http://www.who.int/immunization/topics/pertussis/en/index.htmL

  8. Cherry J. Epidemiological, clinical and laboratory aspects of pertussis in adults. Clin Infect Dis 1999: 28:S112-117.

  9. Ulloa-Gutierrez R, Avila-Aguero M. Pertussis in Latin America: current situation and future vaccination challenges. Expert Rev Vaccines 2008;7:1569-1580.

  10. Anuarios de mortalidad y boletín epidemiológico [internet]. México DF, Dirección General de Epidemiología, 2009-[citado 2011, Noviembre 30]. Disponible en: http://www.dgepi.salud.gob.mx/2010/plantilla/inicio_anuarios.htmL

  11. Bisgard KM, Pascual FB, Ehresmann KR, Millar CA, et al. Infant pertussis: Who was the source? Pediatr Infect Dis J 2004;23:985-989.

  12. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005;24:S104-108.

  13. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007;26:293-299.

  14. Pérez-Miravete A, Pérez-De la Mora S. Encuesta serológica para investigar infecciones por parapertussis en México. Salud Publica Mex 1966;26:235-244.

  15. Gutiérrez G, Ruiz-Gómez J. Seroepidemiología de diez padecimientos infecciosos en niños de la Ciudad de México: sarampión, rubéola, parotiditis, tifoidea, tos ferina, amibiasis, influenza e infecciones por adenovirus, micoplasma pneumoniae y herpes simple. Gaceta Med Mex 1973;105:529-541.

  16. Álvarez MT, Gutiérrez G. Encuesta serológica en niños de la Ciudad de México. Bol Med Hosp Infant (Mex) 1973;30:43-50.

  17. Sapián-López LA, Valdespino JL, Salvatierra B, Tapia-Conyer R, Gutiérrez G, et al. Seroepidemiology of whooping cough in Mexico. Salud Publica Mex 1992;34(2):177-185.

  18. Guerrero ML, Greugelman G, Moreno-Espinosa S, Ramos-Cervantes P, Casas-Muñoz A, Reyes González L, et al. Population Based Incidence of Pertussis among Junior High School Students in Mexico City, 2008-2009 Posters. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2010 Sep 12-15; Boston, Massachusets.

  19. Nooitgedagt JE, de Greeff SC, Elvers BH, de Melker HE, et al. Seroprevalence of Bordetella pertussis infection during pregnancy measured by IgG antibodies against pertussis toxin. Clin Infect Dis 2009;49:1086-1089.

  20. Grupo de expertos en vacunación contra tos ferina, Beltrán Silva S, Cervantes Apolinar Y, Cherry JD, Conde González C, Gentile A, et al. Consensus on the clinical andmicrobiologic diagnosis of Bordetella pertussis, and infection prevention. Expert Group on Pertussis Vaccination. Salud Pública Mex 2011;53:57-65.

  21. Consejo Nacional de Vacunación. Manual de vacunación 2008-2009. México, DF: CONAVA 2008;405 (publicación del Gobierno Federal).

  22. Lavine J, Broutin H, Harvill ET, Bjørnstad ON. Imperfect vaccine-induced immunity and whooping cough transmission to infants. Vaccine 2010;29:11-16.

  23. Kretsinger K, Broder KR, Cortese MM, Joyce MP, Ortega-Sanchez I; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among healthcare personnel. MMWR Recomm Rep 2006;55:1-37.

  24. Centers for Disease Control and Prevention (CDC). Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged <12 Months-Advisory Committee on Immunization Practices(ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1424-1426.

  25. Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a pre pregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011;30:608-610.

  26. Halperin BA, Morris A, Mackinnon-Cameron D, Mutch J, Langley JM, et al. Kinetics of the antibody response to tetanusdiphtheria- acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011;53(9):885-892.

  27. Van Rie A, Wendelboe AM, Englund JA. Role of Maternal Pertussis Antibodies in Infants. Pediatr Infect Dis J 2005;24:S62-65.

  28. Chucri TM, Monteiro JM, Lima AR, Salvador MLB, Kfoury JR, Miglino MA. A review of immune transfer by the placenta. J Reprod Immunol 2010;87:14-20.

  29. Kuehn BM. Mothers Take Physician´s Advice on Vaccines. JAMA 2010;304:2577-2578.

  30. Cheng PJ, Huang SY, Shaw SW, Kao CC, et al. Factors influencing women’s decisions regarding pertussis vaccine: A decision-making study in the Postpartum Pertussis Immunization Program of a teaching hospital in Taiwan. Vaccine 2010; 28:5641-5647.




2020     |     www.medigraphic.com